Scarica l'app Stockscreener
318.85
3.01%
-9.88
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Aberdeen Group plc Has $52.83 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
10 Best Future Stocks to Buy for the Next 5 Years - Insider Monkey
Alnylam Pharmaceuticals (ALNY) Presents Vutrisiran ATTR-CM Data at ACC.26 - Insider Monkey
Alnylam CEO Greenstreet sells $2.23 million in stock - Investing.com
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Data And Partnerships At ACC.26 - simplywall.st
Alnylam Data Update Highlights RNAi Potential And Undervalued Share Price - sahmcapital.com
Barclays Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $527 - Moomoo
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up - 24/7 Wall St.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Combines Strong Growth with a Technical Breakout Setup - ChartMill
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Why Alnylam Pharmaceuticals Inc. (ALNY) is One of the Best High Growth Healthcare Stocks to Buy Now - insidermonkey.com
Hemophilia B Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharma, CSL Behring, uniQure, Novo Nordisk - Barchart
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Alnylam (ALNY) Highlights Breakthrough Vutrisiran Data at ACC An - GuruFocus
Alnylam's (ALNY) Zilebesiran Shows Promising Phase 2 Safety Data - GuruFocus
Alnylam presents cardiovascular data at ACC conference - Investing.com
Alnylam heart drug showed gains seen in patients 11 years younger - Stock Titan
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $360 - Moomoo
Redburn Atlantic Initiates Coverage of Alnylam Pharmaceuticals (ALNY) with Buy Recommendation - MSN
5 High Growth Healthcare Stocks to Buy Now - Insider Monkey
AI-Enabled ATTR-CM Care Pathway Initiative Might Change The Case For Investing In Alnylam Pharmaceuticals (ALNY) - simplywall.st
How Alnylam Pharmaceuticals Inc. (ALNY) Affects Rotational Strategy Timing - Stock Traders Daily
Assenagon Asset Management S.A. Sells 54,791 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
The European Commission Approves Alnylam’s AMVUTTRA - MSN
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR FranchiseSlideshow (NASDAQ:ALNY) 2026-03-26 - Seeking Alpha
3 Stocks Trading Below Estimated Intrinsic Value By Up To 46.8% - simplywall.st
Vanguard amends 13G/A; reports 0 shares in Alnylam (ALNY) - Stock Titan
H.C. Wainwright reiterates Alnylam stock rating at buy, $510 target - Investing.com
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
SG Americas Securities LLC Buys 59,071 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam (ALNY) Targets 25% CAGR with Innovative Therapies - Insider Monkey
Avidity Partners Management LP's Alnylam Pharmaceuticals Inc(ALNY) Holding History - GuruFocus
Alnylam (ALNY) jumps 6.7% as investors refocus on TTR franchise after company webinar - Quiver Quantitative
Chardan Capital Reaffirms "Buy" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
ALNY: HC Wainwright & Co. Reiterates Buy Rating with $510 Target - gurufocus.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given "Buy" Rating at HC Wainwright - MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness - simplywall.st
Alnylam Ties AI Partnerships To ATTR CM Growth And Access Story - Yahoo Finance
Alnylam teams up with Viz.ai and American Heart Association to advance ATTR-CM care - MSN
Narrow-Moat Alnylam's Growth Driven By Strong Demand For Amvuttra in ATTR-CM - morningstar.com
Immutrin raises $87M to advance drug for progressive heart disease - BioPharma Dive
Morgan Stanley reiterates Alnylam stock Equalweight rating at $360 - Investing.com
Alnylam Pharmaceuticals Touts AMVUTTRA ATTR-CM Momentum, Raises 2026 TTR Revenue Outlook - MarketBeat
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association - Business Wire
Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis - Business Wire
Alnylam partners with Viz.ai, AHA on ATTR-CM diagnosis efforts - Investing.com
Congress Asset Management Co. Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Hudson Bay Capital Management LP Lowers Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Chart Watch: Does Alnylam Pharmaceuticals Inc have a sustainable dividend2026 EndofYear Setup & Weekly High Return Forecasts - baoquankhu1.vn
Growth Review: What analysts say about Alnylam Pharmaceuticals Inc stockQuarterly Performance Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - MSN
Alnylam Pharmaceuticals (ALNY) reports $3B 2025 revenue driven by 151% TTR franchise surge - MSN
0.44%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):